Introduction
============

It is widely recognised that regular physical activity is beneficial to both physical and mental health[@b1] It is associated with reduced risk from chronic diseases, including coronary heart disease (CHD)[@b2] and has been shown to be positively linked to mental health,[@b3] including depression.[@b4] Exercise referral schemes (ERS) can target specific patient or population subgroups with such conditions by providing contact with qualified exercise professionals (EP) and access to tailored programmes promoting physical activity.

Despite the rapid growth of ERS in the UK, the evidence base for their effectiveness and cost effectiveness is equivocal. The latest systematic review evidence prior to this study identified six randomised controlled trials from the UK,[@b5] where a modest but statistically significant improvement in activity with a combined RR of 1.2 (95% CI 1.06 to 1.35) was partly explained by poor rates of uptake and adherence, and a lack of intervention relapse-prevention strategies. Overall, results were consistent with previous reviews in that ERS increased physical activity in individuals who were already slightly active,[@b6] [@b7] increases were not maintained long-term[@b7] and scheme attendance was poor.[@b8] International cost-effectiveness evidence was also equivocal,[@b5] [@b9] with a pre-study review[@b10] identifying nine studies varying from €348 to €86 877 (£304 to £75 982) per quality adjusted life year (QALY) depending on scheme intensity.

In light of this, and the development of variable localised ERS throughout the UK, rigorous evidence is needed to distinguish scheme content that facilitates uptake and adherence and promotes long-term improvements in activity.[@b11] This paper reports an independent evaluation of the Welsh Government\'s National Exercise Referral Scheme (NERS) operating in 12 local health board (LHB) areas in Wales, UK, assessing its effectiveness and cost effectiveness in increasing physical activity and reducing anxiety and depression among patients referred for CHD risk and/or anxiety, depression and stress.

Methods
=======

Study design
------------

A pragmatic randomised controlled trial, with nested process and economic evaluations (for full details, see published study protocol[@b12]).

Recruitment of participants
---------------------------

Those eligible for the scheme were sedentary and had at least one medical condition ([table 1](#tbl1){ref-type="table"}). Patients were identified opportunistically by clinicians in normal practice and were provided with basic trial information by the clinician who completed a referral form forwarded to the evaluation team. Those referred for reasons other than CHD and mental health could access the scheme outside of the trial, while those referred with CHD risk factors and/or mild to moderate anxiety, depression or stress were eligible for the trial and were sent full informed consent materials and a brief baseline questionnaire, with non-responders sent a repeat mailing 2 weeks later. The postal questionnaire requested demographic details, post code of residence and the general practice physical activity questionnaire (GPPAQ).[@b13] Eligible patients declining to participate in the trial entered a 12-month waiting list.

###### 

Scheme inclusion/exclusion criteria used by clinicians in normal practice and trial eligibility

  Scheme inclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Scheme exclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Trial eligibility
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  The patient must be **sedentary** (defined as not moderately active for ≥3 times per week or deconditioned through age or inactivity), and have at least one of the following medical conditions: CHD risk factorsRaised blood pressure more than 140/90 (either) but \<180/100 (either)Weight managementBMI \>28Controlled diabetesImpaired glucose toleranceHigh cholesterol \>5.0Family history of heart disease or diabetesReferral from Cardiac Rehabilitation Schemes (only from phase IV)Mental healthMild anxiety, depression or stressMusculoskeletalAt risk of osteoporosisArthritis (mild)Poor mobilityMusculoskeletal pain including back painRespiratory/pulmonaryCOPDMild/moderate well controlled(asthma, bronchitis, emphysema)Neurological conditionsMultiple sclerosisOtherSmokerChronic fatigue   Aged ≤16 yearsUnstable anginaBlood pressure 180/100 (in either) or above and/or uncontrolled or poorly controlled hypertensionCardiomyopathyUncontrolled tachycardiaCardiac arrhythmiaValvular heart diseaseCongenital heart diseaseUnexplained dizzy spellsExcessive or unexplained breathlessness on exertionUncontrolled or poorly controlled diabetesUncontrolled or poorly controlled epilepsyHistory of falls or dizzy spells in the last 12 monthsUncontrolled or poorly controlled asthma (severe COPD)First 12 weeks of pregnancyAwaiting medical investigationAneurysmsHistory of cerebro-vascular diseaseUnstable/newly diagnosed angina (within 6 months)Established coronary heart disease (including myocardial infarction)Any other uncontrolled condition   The patient must be **sedentary** and have at least one of the following condition:CHD risk factorsraised blood pressure more than 140/90 (either) but \<180/100 (either)weight managementBMI \>28controlled diabetesimpaired glucose tolerancehigh cholesterol \>5.0family history of heart disease or diabetesreferral from Cardiac Rehabilitation Schemes (only from phase IV), and orMental healthmild anxiety, depression or stress

BMI, body mass index; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.

Randomisation
-------------

Each participant who consented and returned a completed baseline questionnaire was assigned a unique ID and entered sequentially into the study database. These were randomly assigned to the intervention ERS or control trial arm using a random number generator, with gender and LHB as stratification variables. Randomisation of forwarded referral forms occurred every 2 weeks, with treatment allocation blind and remote from participants and practitioners.

Intervention
------------

The intervention followed a standardised protocol and was delivered at leisure centres by exercise professionals (EP) in each LHB[@b14] [@b15] ([box 1](#box1){ref-type="boxed-text"}). The content, duration and intensity of the scheme were designed to promote adherence and long-term improvements in activity. Consultations were based on motivational interview[@b16] principles which facilitated patient-centred achievable goals, and included relapse-prevention strategies at 4 and 16 weeks to review goals and encourage attendance.[@b14] The primary goal was for participants to achieve 30 min of moderate physical activity on at least 5 days per week. EPs delivering the programme were not directly aware of whether or not a client was a trial participant but could potentially identify this on the basis of the reason for referral. Blinding of participants was not feasible. The control group received usual care and a leaflet highlighting the benefits of exercise, and were given the addresses of local facilities.

###### Delivery of the Welsh National Exercise Referral Scheme (NERS)

### 16-week tailored programme of exercise supervised by a qualified exercise professional

-   Initial consultation with exercise professional on entry: lifestyle questionnaire, health check (resting heart rate, blood pressure, body mass index and waist circumference), introduction to leisure centre facilities, motivational interview and goal setting.

-   Access to one-to-one exercise instruction and/or group exercise classes. Discounted rate for exercise activities, £1 per session.

-   Four-week telephone contact with exercise professional---review of goals, motivational interview, relapse prevention.

-   Sixteen-week consultation with exercise professional---review of goals, motivational interview, health check, lifestyle questionnaire, service evaluation questionnaire[@b14] and advice on continuing with exercise after the programme.

### Post-16-week activities

-   8-months telephone contact by exercise professional to ask about their exercise behaviour and relapse prevention.

-   12-months review including repeat of health check carried out at entry and Chester fitness step test.[@b15]

Sample size
-----------

Sample size was determined to detect a difference in total minutes of weekly activity at 12 months, with 1052 participants in each group providing 90% power to detect an effect size of 0.15 with no loss to follow-up and, more realistically, 87% and 84% power to detect an effect size of 0.15 if 20% and 25%, respectively, of randomised participants who were lost to follow-up.

Outcome measures
----------------

The primary outcome was total minutes of weekly physical activity at 12-month follow-up, assessed using the 7-day physical activity recall (7D-PAR)[@b17] administered by telephone[@b18] with interviewees blind to group allocation. For those telephone respondents unwilling to complete the 7D-PAR, the briefer GPPAQ measure was administered where possible.

A postal questionnaire was also sent to all study participants at 6 and 12 months, with non-responders sent a repeat mailing 2 weeks later. At 6 and 12 months, participants completed an adapted Client Service Receipt Inventory,[@b19] the health-related quality of life measure EQ-5D[@b20] and willingness-to-pay question.[@b21] The outcome measure for the economic analysis was the QALY derived using the EQ-5D, a generic preference-based instrument for measuring health-related quality of life.[@b20] The Client Service Receipt Inventory questionnaire[@b19] asked participants to recall their contacts with NHS primary care (including prescribing) and secondary care services over the preceding 6 months (baseline) and at 6 and 12 months after baseline. The questionnaire at 12 months also included a question asking participants how much (in UK pounds) they were, in theory, willing to pay for exercise sessions through NERS.[@b21] At 12 months, the questionnaire included the Baecke Questionnaire of Habitual Physical Activity (Baecke)[@b22] and the Hospital Anxiety and Depression Scale (HADS) (1983)[@b23] to assess depression and anxiety as secondary outcomes.

Analysis
--------

As the primary outcome (7-D PAR) has a highly skewed and bimodal distribution, it was recoded according to approximate quintiles as a five-level ordinal variable, and proportional odds ordinal regression models were used with the stratification variables (gender, LHB area, age group (16--44, 45--59, 60+)) and baseline activity level (GPPAQ) as covariates. Secondary analysis excluded baseline activity level as a covariate. Analyses were repeated with imputed values for those who did not complete the 7-D PAR, but who did complete either the Baecke or GPPAQ at 12 months, using stochastic imputation based on their Baecke or GPPAQ measures. Subgroup analyses for gender, age group (16--44, 45--59, 60+), referral reason (mental health only, CHD only, or combination of CHD and mental health), and tertile of Welsh Index of Multiple Deprivation obtained for the lower-layer super-output area of the participants\' postcode of residence,[@b24] was assessed by including the main effect and interaction in separate models. We used the same approach with linear regression to explore our secondary outcome measures (HADS) for mental health referrals, or those referred for mental health/CHD combined. The analyses of HADS among all participants are secondary to this analysis. Analyses were conducted on an intention-to-treat basis with the statistician unaware of how the treatment group variable was coded. For each outcome per protocol, analyses to identify whether outcomes vary in terms of adherence to the programme replaced the binary intervention variable with a three-level programme attendance variable; full attendance (for 16 weeks), partial attendance (1--16 weeks), and no exposure to programme (control group or non-attender).

Economic evaluation
-------------------

Costs and benefits of NERS were estimated from a public sector perspective and were not discounted, as follow-up was for 1 year. A primary cost-utility analysis was conducted using the base-case intervention cost per participant (£385; n=3530). As EQ-5D was not included in the minimal data collection at baseline in this trial, conservatively, 6-month EQ-5D values were used as a baseline estimate to generate an incremental cost-effectiveness ratio (ICER) at 12 months and cost effectiveness acceptability curve to compare with the National Institute of Health and Clinical Excellence (NICE) cost per QALY threshold of £20 000--£30 000.[@b25] National unit costs were applied to service use frequency data to estimate total costs of service use for patients,[@b26; @b27; @b28] and cost per QALY estimates were calculated using utility weights from EQ-5D.[@b29] When EQ-5D data were missing for 1 or 2 domains in the 5-domain scale (n=26), stochastic imputation was used. A participant payment of either £1 or £2 per session (based on the findings from our willingness-to-pay analysis) was included in the sensitivity analysis, with a mean attendance of 2 sessions per week for the full 16-week programme at either £32 or £64. Economic subgroup analysis was conducted for reason of referral, age group, gender and adherence.[@b30] Cost-effectiveness analysis was conducted using Stata SE version 10. A nonparametric Mann--Whitney U test was used to compare HR-QoL due to the skewedness of the EQ-5D data.

Results
=======

Participant flow and follow-up
------------------------------

[Figure 1](#fig1){ref-type="fig"} shows participant flow through the study and numbers available for analysis; 1479 (68.5%) for 7D-PAR, 1795 (83.1%) for imputed 7D-PAR and 992 (45.9%) for HADS. Response rates were similar in the two groups. Of those allocated to the intervention, 43.8% (n=473) completed the 16-week programme, 41.3% (n=446) started the programme but did not complete it and 14.9% (n=161) failed to attend. [Table 2](#tbl2){ref-type="table"} shows baseline characteristics for those completing 7D-PAR (n=1479) and HADS measures (n=992) at 12-month follow-up. Although there is some evidence of greater loss to follow-up among younger participants and those referred in whole or part for mental health reasons, there was no strong evidence of differential loss to follow-up in terms of gender or deprivation.

![Flow diagram of the study. EQ5D, EuroQol---5 Dimensions; HADS, Hospital Anxiety and Depression Scale; NERS, National Exercise Referral Scheme; 7-D PAR, 7-day physical activity recall.](jech-2011-200689fig1){#fig1}

###### 

Comparison of demographic characteristics by trial arm at baseline and for EuroQol---5 Dimensions (EQ5D) and 12-month outcomes

                                                     Baseline     EQ5D         7-D PAR      HADS                                                
  -------------------------------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------
  Reasons for referral                                                                                                                          
   CHD only                                          71.3 (770)   73.1 (789)   76.8 (307)   77.6 (309)   74 (536)     75.8 (572)   75.2 (360)   76.6 (393)
   Mental health only                                3.8 (41)     3.5 (38)     3.3 (13)     3.3 (13)     3.5 (25)     3.1 (23)     2.9 (14)     2.9 (15)
   CHD and mental health                             24.9 (269)   23.4 (253)   20.0 (80)    19.1 (976)   22.5 (163)   21.2 (160)   21.9 (105)   20.5 (105)
  Age group                                                                                                                                     
   16--44                                            29.9 (322)   30.1 (323)   17.3 (69)    17.8 (71)    26.6 (192)   26.0 (196)   18.8 (90)    19.5 (100)
   45--59                                            34.5 (371)   32.7 (352)   33.8 (135)   34.0 (136)   35.3 (255)   34.3 (258)   34.7 (166)   35.1 (180)
   60+                                               35.6 (383)   37.2 (400)   49.0 (196)   48.0 (191)   38.1 (275)   39.7 (299)   46.4 (222)   45.4 (233)
  Gender                                                                                                                                        
   Male                                              34.4 (372)   34.5 (373)   33.8 (135)   32.7 (130)   34.5 (250)   33.3 (251)   35.1 (168)   33.1 (170)
   Female                                            65.6 (708)   65.5 (707)   66.3 (265)   67.0 (268)   65.5 (474)   66.7 (504)   64.9 (311)   66.9 (343)
  Welsh index of multiple deprivation tertile                                                                                                   
   Low                                               34.4 (361)   32.3 (340)   35.0 (140)   32.2 (128)   37.1 (262)   33.5 (246)   37.5 (173)   32.9 (165)
   Middle                                            34.1 (358)   32.5 (342)   33.5 (134)   38.0 (152)   32.4 (232)   35.0 (257)   34.3 (158)   37.3 (187)
   High                                              31.4 (330)   35.2 (370)   27.8 (111)   27.9 (111)   30 (212)     31.6 (232)   28.2 (130)   29.7 (149)
  General practice physical activity questionnaire                                                                                              
   Inactive                                          59.2 (623)   60.6 (643)   56.3 (225)   60.8 (242)   58.2 (411)   61.4 (455)   59.0 (276)   60.5 (306)
   Moderate inactive                                 16.1 (170)   15.1 (160)   14.8 (59)    13.6 (54)    15.6 (116)   15.3 (113)   14.3 (67)    14.0 (71)
   Moderate active                                   17.2 (181)   15.2 (161)   17.8 (71)    14.6 (58)    19.3 (136)   14.8 (110)   17.5 (82)    15.2 (77)
   Active                                            7.5 (79)     9.2 (97)     8.5 (34)     9.8 (39)     6.4 (49)     8.5 (63)     9.2 (43)     10.3 (52)
   Missing                                           \(27\)       \(19\)       2.8 (11)     1.3 (5)                                             
  Employment                                                                                                                                    
   Employed                                          32.7 (346)   28.4 (300)   26.3 (105)   24.6 (98)    32.7 (232)   29.5 (218)   27.0 (131)   27.7 (139)
   Retired                                           30 (318)     32.9 (348)   41.3 (165)   41.7 (166)   32.7 (232)   35.1 (259)   38.8 (183)   40.2 (202)
   Housework                                         18.8 (199)   20.3 (214)   16.3 (65)    18.9 (75)    17.0 (121)   20.6 (152)   17.0 (80)    18.5 (93)
   Other                                             18.5 (196)   18.5 (195)   16.3 (62)    13.1 (52)    17.6 (125)   14.8 (109)   16.5 (78)    13.6 (68)
   Missing                                           1.9 (21)     2.1 (23)     0.8 (3)      2.0 (8)                                             
  Education                                                                                                                                     
   Beyond min school leaving age                     52.1 (557)   53.0 (570)   57.0 (228)   58 (231)     51.5 (370)   54.6 (410)   58.7 (280)   55.5 (284)
  Total (n)                                          1080         1080         400          398          724          755          479          513

CHD, coronary heart disease; 7-D PAR, 7-day physical activity recall.

Baseline data
-------------

Participants were aged between 16 and 88 years (mean 52, SD 14.7), predominately women (66%) and the vast majority classed themselves as white (96%). [Table 2](#tbl2){ref-type="table"} shows participants were most likely to be referred for CHD risk factors only (72%) or in combination with mental health issues (24%) and classed themselves as inactive (58.6%) or moderately inactive (15.3%), with 24% defining themselves as either active or moderately active. The economic analysis was based on 55% (n=798) of the participants in the effectiveness analysis. The economic sample contained fewer younger participants (n=140, 18%) than the main trial (n=1423, 30%), and included a higher proportion of participants who were referred for CHD risk factors only (n=616, 77%) compared with the main sample (n=1559, 71%). More of them also completed the 16-week programme (62%, n=247), with fewer partial (32%, n=123) and non-attenders (8%, n=30). The intervention and control groups were similar for all baseline characteristics.

Intervention effects
--------------------

[Table 3](#tbl3){ref-type="table"} presents the 12-month median scores and inter-quartile range for the 7-D PAR and means and CIs for depression and anxiety scores by trial arm and age, gender, Welsh Index of Multiple Deprivation, adherence, reason for referral and baseline GPPAQ. [Table 4](#tbl4){ref-type="table"} shows the results of the regression analyses for each of the primary outcomes at 12-month follow-up. For all participants, those in the intervention group had higher levels of physical activity than those in the control, but this was of borderline statistical significance. Among those referred for CHD risk factors, the intervention group reported significantly higher levels of activity, but there was no difference among those referred wholly or partially for mental health reasons. Among this group of referrals, those randomised to NERS had significantly lower levels of both depression and anxiety.

###### 

Twelve-month follow-up: medians and IQR for 7-day PAR and means and 95% confidence intervals for HADS by trial arm and covariates

  Co-variate                      Level                     7-day PAR total minutes of exercise median (IQR)   HADS anxiety score mean (95% CI)   HADS depression score mean (95% CI)                                                             
  ------------------------------- ------------------------- -------------------------------------------------- ---------------------------------- ------------------------------------- ---------------------------- ---------------------------- ---------------------------
  All                                                       200 (60, 435) n=724                                165 (50, 370) n=755                7.82 (7.39 to 8.25) n=472             8.35 (7.92 to 8.77) n=502    6.14 (5.73 to 6.54) n=471    6.93 (6.53 to 7.32) n=506
  Age                             16--44                    210 (62.5, 452.5) n=192                            207.5 (60, 425) n=196              9.05 (8.08 to 10.07) n=88             10.80 (9.97 to 11.63) n=95   7.39 (6.39 to 8.40) n=89     8.70 (7.87 to 9.54) n=98
  45--59                          210 (60, 520) n=255       127.5 (35, 355) n=258                              9.39 (8.64 to 10.13) n=165         9.13 (8.39 to 9.87) n=177             7.10 (6.38 to 7.81) n=164    7.81 (7.09 to 8.52) n=177    
  60+                             185 (50, 390) n=275       175 (60, 355) n=299                                6.14 (5.57 to 6.70) n=218          6.73 (6.16 to 7.30) n=230             4.91 (4.40 to 5.43) n=217    5.50 (4.98 to 6.01) n=231    
  Gender                          Female                    200 (60, 455) n=474                                150 (42.5, 345) n=504              7.64 (7.10 to 8.17) n=308             8.83 (8.32 to 9.33) n=333    5.70 (5.21 to 6.19) n=305    7.22 (6.74 to 7.69) n=337
  Male                            205 (75, 395) n=250       210 (60, 420) n=251                                8.16 (7.43 to 8.89) n=164          7.40 (6.65 to 8.16) n=169             6.94 (6.25 to 7.63) n=166    6.35 (5.65 to 7.05) n=169    
  WIMD                            Low                       205 (80, 400) n=262                                165 (35, 360) n=246                7.19 (6.46 to 7.91) n=171             7.29 (6.56 to 8.02) n=162    5.43 (4.83 to 6.03) n=167    6.28 (5.59 to 6.97) n=164
  Middle                          205 (60, 557.5) n=232     160 (60, 405) n=257                                7.85 (7.13 to 8.56) n=156          8.28 (7.59 to 8.98) n=183             6.30 (5.60 to 7.00) n=157    6.54 (5.91 to 7.16) n=183    
  High                            170 (45, 390) n=212       172.5 (60, 392.5) n=232                            8.53 (7.65 to 9.41) n=127          9.49 (8.69 to 10.29) n=145            6.81 (5.96 to 7.67) n=129    8.25 (7.49 to 9.01) n=147    
  Adherence                       0 wk.                     140 (20, 370) n=79                                 NA                                 9.17 (7.73 to 10.61) n=47             NA                           7.36 (6.05 to 8.66) n=45     NA
  \> 0 to \<16 wk. adherence      162.5 (37.5, 385) n=284   NA                                                 8.63 (7.86 to 9.40) n=159          NA                                    7.14 (6.39 to 7.89) n=158    NA                           
  16 wk.                          240 (90, 510) n=361       NA                                                 7.09 (6.55 to 7.64) n=266          NA                                    5.34 (4.85 to 5.84) n=268    NA                           
  Reason for referral             CHD only                  210 (80, 442.5) n=536                              170 (60, 360) n=572                6.95 (6.49 to 7.41) n=355             7.33 (6.88 to 7.78) n=386    5.45 (5.03 to 5.87) n=355    6.18 (5.76 to 6.60) n=389
  Mental health only              220 (30, 315) n=25        240 (60, 450) n=23                                 12.85 (9.96 to 15.73) n=13         12.07 (9.55 to 14.58) n=15            9.69 (6.77 to 12.62) n=13    9.27 (6.34 to 12.19) n=15    
  CHD and mental health reasons   155 (40, 420) n=163       147.5 (32.5, 392.5) n=160                          10.15 (9.25 to 11.06) n=104        11.68 (10.81 to 12.55) n=101          8.06 (7.09 to 9.03) n=103    9.42 (8.51 to 10.33) n=102   

HADS, Hospital Anxiety and Depression Scale; WIMD, Welsh index of multiple deprivation; 7-D PAR, 7-day physical activity recall.

###### 

Main effects and interaction effects - ORs and 95% CIs from ordinal logistic regression models examining impacts of NERS on physical activity and B coefficients and 95% CIs from linear regression models examining impacts of NERS on depression and anxiety

  Effect                                                                              Group                                                                             7-D PAR                 7-D PAR plus imputed values   HADS depression             HADS anxiety
  ----------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ----------------------- ----------------------------- --------------------------- ------------------------
  Main effects                                                                        Whole sample                                                                                                                                                        
  All covariates included (n=1443/1749/959/956)[†](#table-fn1){ref-type="table-fn"}   1.19 (0.99, 1.43)                                                                 1.18 (0.99, 1.42)       −0.71\* (−1.25, −0.17)        −0.54 (−1.12, 0.35)         
  Baseline GPPAQ omitted (n=1475/1788/976/973)[†](#table-fn1){ref-type="table-fn"}    1.20\* (1.00, 1.45)                                                               1.19\* (1.00, 1.42)     −0.74\* (−1.28, −0.20)        −0.49 (−1.06, 0.08)         
  CHD only                                                                                                                                                                                                                                                
  All covariates included (n=1081/1302/732/729)[†](#table-fn1){ref-type="table-fn"}   1.29\* (1.04, 1.60)                                                               1.26\* (1.02, 1.57)     −0.60\* (−1.18, −0.02)        −0.32 (−0.95, 0.31)         
  Baseline GPPAQ omitted (n=1105/1329/743/740)[†](#table-fn1){ref-type="table-fn"}    1.35\*\* (1.09, 1.67)                                                             1.30\* (1.05, 1.60)     −0.64\* (−1.22, −0.03)        −0.27 (−0.90, 0.35)         
  MH only or MH and CHD                                                                                                                                                                                                                                   
  Interaction effects                                                                 All covariates included (n=362/447/227/227)[†](#table-fn1){ref-type="table-fn"}   1.06 (0.73, 1.55)       1.04 (0.72, 1.52)             −1.39\* (−2.60, −0.18)      −1.56\* (−2.75, −0.38)
  Baseline GPPAQ omitted (n=370/459/233/233)[†](#table-fn1){ref-type="table-fn"}      0.94 (0.65, 1.36)                                                                 1.00 (0.69, 1.36)       −1.32\* (−2.54, −0.10)        −1.52\* (−2.68, −0.37)      
  Deprivation (n=1405/1698/929/926)[†](#table-fn1){ref-type="table-fn"}                                                                                                                                                                                   
   Medium x intervention                                                              1.08 (0.69 to 1.70)                                                               0.98 (0.63 to 1.55)     0.80 (−0.50 to 2.09)          −0.24 (−1.64 to 1.15)       
   High x intervention                                                                0.83 (0.52 to 1.32)                                                               0.80 (0.52 to 1.25)     −0.13 (−1.50 to 1.25)         −0.46 (−1.94 to 1.02)       
  Adherence level (n=1443/1749/959/956)[†](#table-fn1){ref-type="table-fn"}                                                                                                                                                                               
   Partial                                                                            1.00 (0.78 to 1.29)                                                               1.00 (0.79 to 1.27)     −0.12 (−0.90 to 0.65)         −0.12 (−0.84 to 0.82)       
   Full                                                                               1.46\* (1.17 to 1.84)                                                             1.40\* (1.11 to 1.79)   −1.24\* (−1.88 to --0.61)     −1.12\* (−1.80 to --0.44)   
  Gender (n=1443/1749/959/956)[†](#table-fn1){ref-type="table-fn"}                                                                                                                                                                                        
   Male x intervention                                                                0.75 (0.51 to 1.10)                                                               0.74 (0.51 to 1.07)     2.10\* (0.98 to 3.23)         1.93\* (0.72 to 3.14)       
  Age (n=1443/1749/959/956)[†](#table-fn1){ref-type="table-fn"}                                                                                                                                                                                           
   45--59 x intervention                                                              1.36 (0.84 to 2.21)                                                               1.36 (0.84 to 2.18)     0.61 (−0.94 to 2.16)          2.03\* (0.37 to 3.69)       
   60+ x intervention                                                                 0.99 (0.63 to 1.58)                                                               1.04 (0.67 to 1.62)     0.65 (−0.83 to 2.13)          1.07 (−0.52 to 2.66)        

\*p\<0.05; \*\*p\<0.01.

n represents number of patients in 7-day PAR analyses/7-day PAR plus imputed values/HADS depression/HADS anxiety. All models include gender, LHB area, age group as covariates. Except where stated, all models also include baseline GPPAQ as a further covariate.

CHD, coronary heart disease; GPPAQ, general practice physical activity questionnaire; HADS, Hospital Anxiety and Depression Scale; MH, mental health; 7-D PAR, 7-day physical activity recall.

Subgroup analyses showed effectiveness was highly dependent on adherence, with significantly greater differences in all outcomes among those who completed the 16-week programme compared with those who attended only partially or not at all. There were also significant interactions with gender for both mental health outcomes, with the beneficial effect of the intervention only apparent among women. There was a suggestion that the intervention was more effective on mental health outcomes among the youngest age group (18--44), although this was not statistically significant. Effects did not vary significantly by deprivation status.

Cost effectiveness
------------------

The data on health-related quality of life and adherence to the programme are summarised in [table 5](#tbl5){ref-type="table"}. A significant difference in HR-QoL between the intervention and control groups was found using EQ-5D-VAS. For participants \<44 years of age, the difference between both EQ-5D and VAS scores was significant. 62% (n=247) of the sample upon which economic analysis was undertaken completed the 16-week programme, 32% (n=123) attended fewer than 16 weeks and 8% (n=30) did not attend at all. There were no significant differences in NHS resource use between the intervention and control groups, except that the control groups were referred for significantly more health-related tests (p=\<0.05) (data not presented). In the base-case analysis, the difference in costs between intervention and control group was £327, and the difference in QALYs was 0.027, which generated an ICER point estimate of £12 111 per QALY gained. The probability of the intervention being cost effective was 89% at the NICE threshold of £30 000 per QALY.

###### 

Mean cost-effectiveness outcomes by group over 12 months

  Outcomes at 12 month follow-up   Intervention group mean (SD)   Control group mean (SD)   [\*](#table-fn2){ref-type="table-fn"}p value
  -------------------------------- ------------------------------ ------------------------- ----------------------------------------------
  EQ-5D score (0--1)                                                                        
   Entire sample                   0.64 (0.32) n=395              0.61 (0.32) n=391         0.09
   \<44 years                      0.68 (0.33) n=69               0.54 (0.34) n=71          0.012[\*](#table-fn2){ref-type="table-fn"}
   45--60 years                    0.58 (0.35) n=132              0.59 (0.35) n=131         0.88
   \>60 years                      0.67 (0.28) n=194              0.65 (0.27) n=89          0.37
  EQ-5D VAS (0--100)                                                                        
   Entire sample                   68.8 (18.6) n=397              63.9 (20) n=394           0.0007[\*](#table-fn2){ref-type="table-fn"}
   \<44 years                      67.62 (19.1) n=69              58.3 (20.2) n=71          0.003[\*](#table-fn2){ref-type="table-fn"}
   45--60 years                    66.1 (18.6) n=135              62.0 (19.5) n=133         0.13
   \>60 years                      71.1 (18.2) n=193              67.3 (19.8) n=190         0.07
  Adherence                                                                                 
   Did not attend                  30 (8%)                        NA                        NA
   Attended \<16 weeks             123 (32%)                      NA                        NA
   Attended 16 weeks               247 (62%)                      NA                        NA

Significant (p\<0.05) according to Mann--Whitney test.

EQ5D, EuroQol---5 Dimensions; VAS, visual analogue scale.

The results of sensitivity and subgroup analyses are summarised in [table 6](#tbl6){ref-type="table"}. Using the mean intervention and control group 6-month EQ-5D score as an estimate for the baseline, QALYs resulted in a decrease of the ICER from £12 111 (base case) to £6055 per QALY. When only the control group\'s mean EQ-5D value at 6 months was used as an estimate of baseline QALYs for both control and intervention groups, the ICER point estimate was £7109. This analysis demonstrates that using the 6-month EQ-5D data as an estimate of baseline, QALYs in the base-case analysis was a rather conservative approach. When possible, participant payments of £1 and £2 per session were added to the base-case analysis, the cost per QALY fell to £10 926 and £9741, respectively. Subgroup analyses found that the intervention is likely to be more cost effective in: participants with CHD and/or mental health risk factors compared with participants with a risk of CHD only; female rather than male participants; younger (\<44 years) rather than older individuals. Subgroup analysis based on those who had adhered fully to the 16-week programme indicated a saving of --£367 per QALY gained.

###### 

Cost-effectiveness sensitivity (A) and subgroup analysis (B)

                                                                             Intervention group (n)   Control group (n)   Cost of intervention (£)   ICER (£)   Bootstrapped one-sided 95% CI for ICER (£)   Probability that intervention is cost effective[\*](#table-fn3){ref-type="table-fn"}
  -------------------------------------------------------------------------- ------------------------ ------------------- -------------------------- ---------- -------------------------------------------- --------------------------------------------------------------------------------------
  \(A\) Sensitivity analyses                                                                                                                                                                                 
   Base case                                                                 395                      391                 385                        12 111     58 881                                       89%
   Mean intervention and control EQ-5D at 6 months as estimate of baseline   395                      391                 385                        6055       37 159                                       96%
   Control group mean EQ-5D value at 6 months as estimate of baseline        395                      391                 385                        7109       24 853                                       98%
   Participant payment of £1 per session                                     395                      391                 385--32=353                10 926     69 085                                       91%
   Participant payment of £2 per session                                     395                      391                 385--64=321                9741       64 638                                       92%

                                         Intervention group (n)   Control group (n)   Incremental cost (bootstrapped 95%CI)   Incremental QALY (bootstrapped 95%CI)   ICER (bootstrapped one-sided 95%CI)
  -------------------------------------- ------------------------ ------------------- --------------------------------------- --------------------------------------- -------------------------------------
  \(B\) Subgroup analysis                                                                                                                                             
   Referral reason                                                                                                                                                    
    CHD only                             307                      309                 £239 (−51 to 547)                       0.0183 (−50.0047 to 0.0416)             £13 060 (117 893)
    Mental health (MH) and MH plus CHD   80                       76                  £596 (−5304 to 1616)                    0.058 (0.017 to 0.100)                  £10 276 (50 925)
   Gender                                                                                                                                                             
    Male                                 135                      130                 £322 (−5180 to 792)                     0.0084 (--0.0250 to 0.0400)             £38 333 (254 973)
    Female                               265                      268                 £326 (−589 to 761)                      0.0362 (0.0111 to 0.0623)               £9006 (390 00)
   Age                                                                                                                                                                
    \<44 years                           69                       71                  £68 (−5462 to 678)                      0.0656 (0.0137 to 0.1148)               £1037 (16 418)
    44--60 years                         135                      136                 £577 (−5176 to 1373)                    0.0179 (−0.0194 to 0.0561)              £32 235 (314 108)
    \>60 years                           196                      191                 £244 (−5131 to 586)                     0.0187 (−0.0057 to 0.0424)              £13 048 (153 565)
   Adherence                                                                                                                                                          
    0 weeks                              30                                           £1785 (25 to 4570)                      −0.0114 (−0.0680 to 0.0390)             NA
    \<16 weeks                           123                                          £662 (212 to 1157)                      −0.0084 (−0.0384 to 0.0218)             NA
    16 weeks                             247                                          --£18 (−5310 to 277)                    0.049 (0.0277 to 0.0706)                −£367 (7068)

At the £30 000 per QALY threshold.

EQ5D, EuroQol---5 Dimensions; ICER, incremental cost-effectiveness ratio; QUALY, quality adjusted life year.

Discussion
==========

Among those referred for CHD risk factors only, the NERS in Wales was associated with significantly higher levels of physical activity when compared with normal care. However, among those referred for mental health reasons, either solely or in combination with CHD, there was no difference in physical activity between the NERS and normal care participants at 12-month follow-up. The primary analysis of the trial was of the impact of the scheme on all referrals, and this was of borderline statistical significance, being in effect a pooled estimate of two heterogeneous subgroup effects. Two recent systematic reviews[@b31] [@b32] have highlighted the need to examine variation in effectiveness based on medical condition, a view strongly supported by the current study.

For patients referred for mental health reasons, the scheme was not effective in helping them to increase physical activity. Further planned analyses of data collected at 6 months will allow an assessment of whether the scheme was effective in increasing self-efficacy and motivation to exercise among these patients. Consistent with recent systematic review findings,[@b31] [@b32] patients referred for mental health reasons did appear to benefit in terms of reduced anxiety and depression, particularly in this trial among women and younger patients. This suggests that for these patients, the EP\'s attention and the social contact and support generated by scheme attendance may be the beneficial mechanisms rather than increased physical activity per se, a hypothesis requiring further research.

One of the recent reviews also highlights the importance of scheme uptake, adherence and their predictors in explaining outcomes: NERS uptake at 85% was slightly above the average (80%) found in the review.[@b32] Although only 44% of intervention participants adhered to the scheme throughout, this compares favourably with the pooled rate of 37% across schemes assessed by trials in the review.[@b32] The relationship between adherence, psychosocial processes and 12-month outcomes will be assessed in future papers.

A pre-study review suggested that low-contact and low-intensity physical activity interventions are more cost effective than more intensive interventions.[@b10] NERS is an intensive 16-week programme which we have found to be likely to be cost effective at conventional thresholds, a finding consistent with recent cost-effectiveness reviews,[@b32] [@b33] which modelled lifetime benefits and showed a 51% probability of cost effectiveness at £20 000 per QALY and 88% at £30 000 per QALY.

Strengths and weaknesses of the study
-------------------------------------

A pre-study systematic review of ERS found only six RCTs in the UK and identified a number of shortcomings, including blinding of outcome measurement, the need for long-term follow-up and the generalisability of the study population.[@b5] A more recent review of eight European RCTs[@b31] suggested that substantial heterogeneity in the quality and nature of schemes may have contributed to inconsistent evidence of their effectiveness and identified the need for further high-quality RCTs of theoretically informed approaches to behaviour change (including motivational interviewing). They also highlighted the need to assess subgroup effectiveness.

In NERS, motivational interviewing was used as a clearly identified approach to behaviour change, though implementation checks indicated that it was often poorly delivered[@b16] with data indicating that in practice, the key active ingredients of the programme were the professionals\' support and supervision and interaction with other patients.[@b34] This suggests that scheme effectiveness could be improved with increased attention to fidelity of motivational interviewing. The importance of subgroup analysis based on medical condition is highlighted in the inconsistent outcomes for CHD and mental health referrals observed in the current study. In addition, the primary outcome was collected at 12 months by researchers blinded to condition. Physiological outcomes and objective measures of physical activity were not collected. However, the 7D-PAR is well validated and was administered by telephone which provides a more reliable measure than postal questionnaires.[@b35] Confidence in the robustness of findings is enhanced by the relatively high response rate achieved for the primary outcome (68.5%) compared with equivalent community trials of ERS.[@b5] Using other measures of physical activity (Baecke and GPPAQ) to impute scores for weekly activity for those without a 7D PAR measure provided an enhanced response rate of 83.1%, although it should be acknowledged that GPPAQ was developed as a clinical screening, rather than a data-capture tool.

Significantly, as a pragmatic policy evaluation, results are likely to have high external validity and generalisabilty.[@b36] There was minimal control over the implementation of the intervention, other than randomisation, and it was delivered across Wales by a wide range of professionals to patients from areas covering the full spectrum of socioeconomic circumstances. The NERS in Wales shares many features of similar schemes implemented across the UK.[@b37]

It should also be noted that there was a much lower response rate to the 12-month postal questionnaire, and thus the economic and mental health analyses are based on a smaller number of participants. Although there was no strong patterning in response rates, these may be subject to unmeasured response bias, and it is acknowledged that cost effectiveness is assessed at 12 months only.

As in previous studies,[@b5; @b6; @b7] it should be noted that a significant minority of trial participants, who were referred on the basis of their clinician identifying them as sedentary, reported activity levels at baseline which classed them as active or moderately active by GPPAQ criteria. The inclusion of this subgroup may well have contributed to higher levels of adherence and activity, however, as a pragmatic policy trial it was important that these individuals were not excluded. Given the number of policy and practice constraints that have inhibited such evaluations,[@b11] the current study provides a relatively rare example of a pragmatic randomised trial of a national ERS and demonstrates the feasibility of calls for an increase in such trials of public health interventions.[@b38]

Conclusion
==========

NERS was effective in increasing physical activity among those referred with CHD risk factors. Although there was no increase in physical activity among those referred for mental health reasons, anxiety and depression were reduced. These effects were highly dependent on adherence to the programme. NERS is likely to be cost effective under prevailing payer thresholds.

###### What is already known on this subject

-   Previous evaluations of Exercise Referral Schemess in the UK have found only modest improvements in physical activity in the short term, and there is uncertainty whether such approaches are cost effective. These effects are partly explained by poor rates of uptake and adherence to the schemes and a lack of intervention relapse-prevention strategies.

###### What this study adds

-   At 12-month follow-up, the Wales NERS was associated with increased physical activity among those referred for coronary heart disease risk factors. Among those referred for mental health reasons, there were reductions in depression and anxiety without any increase in physical activity.

-   Programme intensity and the provision of relapse strategies appear to be effective in promoting relatively high rates of adherence to the scheme, which was associated with greater improvements on all outcomes.

###### Policy implications

-   Applying the NICE threshold of £20 000--£30 000 per QALY to wider government spending, the Wales National exercise Referral Scheme has a moderate to high probability of being cost effective.

-   Pragmatic effectiveness trials nested within government policy roll-outs are feasible and provide opportunities to develop generalisable public health intervention research evidence.

The authors thank the scheme\'s coordinators, Elaine McNish and Jeannie Wyatt-Williams and Janine Hale and Chris Roberts of the Welsh government for providing information and ongoing support to facilitate this study. The authors are grateful to all exercise coordinators and professionals and patients that took part in the study. The research was independent and funded by the Welsh Assembly Government. Additional support during writeup was provided by The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement (DECIPHer), a UKCRC Public Health Research: Centre of Excellence. Funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council (RES-590-28-0005), Medical Research Council, the Welsh Assembly Government and the Wellcome Trust (WT087640MA), under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. The Thames Valley Multi-centre Research Ethics Committee (MREC) approved the evaluation of the Welsh NERS on 8 Feb 2007 (Ref: 06/MRE12/85). Due to changes in COREC procedures, an additional Site-Specific Information form (Ref: C/92139/137055/1) was also later submitted to the MREC. Approval from medical directors within each local health board has also been obtained in partnership with local exercise coordinators. The conduct of the study conformed to the principles embodied in the Declaration of Helsinki.

**Contributors:** Principal responsibility for the study was assumed by SMM. LR was the trial manager and responsible for the day-to-day running of the study. GM was responsible for the development and day-to-day running of the mixed-method process evaluation. RTE was responsible for study design and overseeing of the economic evaluation. PL was responsible for the day-to-day running of the economic evaluation. NH was responsible for the cost-effectiveness analysis. NW contributed to the study design and aspects of the process evaluation. NUD was responsible for the design and conduct of aspects of the process evaluation. LM contributed to the study design, conducted sample size calculations, designed the analysis plan and took responsibility for statistical analysis. SM and RTE produced a first draft of the manuscript, and SM was responsible for the final revised version, developing and integrating contributions. All authors read and commented on drafts and approved the final manuscript and had full access to all the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis. SMM acts as guarantor.

**Funding:** This study was supported by the Welsh Government.

**Competing interests:** None.

**Ethics approval:** Ethics approval was provided by the Thames Valley Multi-centre Research Ethics Committee (MREC) approved the evaluation of the Welsh NERS on 8 Feb 2007 (Ref: 06/MRE12/85).

**Provenance and peer review:** Not commissioned; externally peer reviewed.

**Data sharing statement:** Data is still currently being analysed to address secondary research questions.
